BRPI0814479A2 - "método para regular uma atividade de metaloproteinase 9 (mm9), método para identificar um agente capaz de regular especificamente a mmp-9, método de tratar a afecção clínica mediada pela mmp-9, molécula capaz de regular especificamente uma atividade da mmp-9, anticorpo humanizado e composição farmacêutica" - Google Patents

"método para regular uma atividade de metaloproteinase 9 (mm9), método para identificar um agente capaz de regular especificamente a mmp-9, método de tratar a afecção clínica mediada pela mmp-9, molécula capaz de regular especificamente uma atividade da mmp-9, anticorpo humanizado e composição farmacêutica"

Info

Publication number: BRPI0814479A2
Authority: BR; Brazil
Prior art keywords: mmp; regulating; activity; specifically; metalloproteinase
Prior art date: 2007-08-15

Application number

BRPI0814479A

Other languages

English (en)

Inventor

Gabriel Rosenblum

Irit Sagi

Original Assignee

Yeda Res & Dev

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-08-15

Filing date

2008-08-07

Publication date

2016-07-12

2008-08-07 Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev

2016-07-12 Publication of BRPI0814479A2 publication Critical patent/BRPI0814479A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24035—Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
- G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
- G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Neurology (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Neurosurgery (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biophysics (AREA)
Hematology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Mycology (AREA)

BRPI0814479A 2007-08-15 2008-08-07 "método para regular uma atividade de metaloproteinase 9 (mm9), método para identificar um agente capaz de regular especificamente a mmp-9, método de tratar a afecção clínica mediada pela mmp-9, molécula capaz de regular especificamente uma atividade da mmp-9, anticorpo humanizado e composição farmacêutica" BRPI0814479A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US93548607P	2007-08-15	2007-08-15
PCT/IL2008/001082 WO2009022328A2 (en)	2007-08-15	2008-08-07	Regulators of mmp-9 and uses therof

Publications (1)

Publication Number	Publication Date
BRPI0814479A2 true BRPI0814479A2 (pt)	2016-07-12

Family

ID=40351257

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0814479A BRPI0814479A2 (pt)	2007-08-15	2008-08-07	"método para regular uma atividade de metaloproteinase 9 (mm9), método para identificar um agente capaz de regular especificamente a mmp-9, método de tratar a afecção clínica mediada pela mmp-9, molécula capaz de regular especificamente uma atividade da mmp-9, anticorpo humanizado e composição farmacêutica"

Country Status (14)

Country	Link
US (3)	US20110052572A1 (pt)
EP (2)	EP2581445B1 (pt)
JP (1)	JP2010536744A (pt)
KR (1)	KR20100071972A (pt)
CN (1)	CN102083455B (pt)
AU (1)	AU2008288082B2 (pt)
BR (1)	BRPI0814479A2 (pt)
CA (1)	CA2695969A1 (pt)
DK (1)	DK2185175T3 (pt)
ES (1)	ES2406105T3 (pt)
IL (1)	IL222302A (pt)
MX (1)	MX2010001657A (pt)
RU (1)	RU2474433C2 (pt)
WO (1)	WO2009022328A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20100071972A (ko)	2007-08-15	2010-06-29	예다 리서치 앤드 디벨럽먼트 캄파니 리미티드	Ｍｍｐ-9의 조절인자 및 그의 용도
EP2262529A4 (en) *	2008-03-03	2013-05-08	Dyax Corp	METALLOPROTEINASE BINDING PROTEINS 9
KR101930179B1 (ko)	2010-08-27	2018-12-17	길리아드 바이오로직스, 인크.	매트릭스 메탈로프로테이나제 ９에 대한 항체
JP5814800B2 (ja) *	2011-12-28	2015-11-17	株式会社Ｌｓｉメディエンス	神経変性疾患の検出方法
HK1204926A1 (en)	2012-02-29	2015-12-11	吉联亚生物科技有限公司	Antibodies to matrix metalloproteinase 9
HUE030858T2 (en)	2012-07-04	2017-06-28	Hoffmann La Roche	Covalently linked antigen-antibody conjugates
RU2017128512A (ru)	2012-07-04	2019-02-15	Ф. Хоффманн-Ля Рош Аг	Антитела к теофиллину и способы их применения
MX354303B (es)	2012-07-04	2018-02-23	Hoffmann La Roche	Anticuerpos de anti-biotina y metodos de uso.
EP3089759B1 (en)	2014-01-03	2018-12-05	F. Hoffmann-La Roche AG	Covalently linked polypeptide toxin-antibody conjugates
RU2693438C2 (ru)	2014-01-03	2019-07-02	Ф. Хоффманн-Ля Рош Аг	Биспецифичные антитела против гаптена/против рецептора гематоэнцефалического барьера, их комплексы и их применение в качестве челноков гематоэнцефалического барьера
WO2015101587A1 (en)	2014-01-03	2015-07-09	F. Hoffmann-La Roche Ag	Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
JP6313530B1 (ja) *	2015-01-16	2018-04-18	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	標的化成分及びエフェクター成分を有する分子構築物
US20200306283A1 (en)	2016-06-22	2020-10-01	William Warren HARLESS	Cancer treatment and metastasis inhibition using an anti-cancer stem cell agent in combination with a neu1 sialidase inhibitor or a cytokine inhibitor after primary cancer treatment
US20210261971A1 (en) *	2018-06-25	2021-08-26	University Of Southern California	Compositions and methods for ameliorating tissue injury, enhancing liver regeneration and stem cell therapies

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL154600B (nl)	1971-02-10	1977-09-15	Organon Nv	Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl)	1970-11-10	1977-09-15	Organon Nv	Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl)	1970-12-28	1977-09-15	Organon Nv	Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en)	1971-06-21	1975-08-26	Biological Developments	Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en)	1971-09-01	1974-12-10	W Dreyer	Immunological reagent and radioimmuno assay
US3867517A (en)	1971-12-21	1975-02-18	Abbott Lab	Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl)	1972-05-11	1983-06-01	Akzo Nv	Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en)	1973-03-12	1974-11-26	H Mcconnell	Process for assaying for biologically active molecules
US3935074A (en)	1973-12-17	1976-01-27	Syva Company	Antibody steric hindrance immunoassay with two antibodies
US3996345A (en)	1974-08-12	1976-12-07	Syva Company	Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en)	1974-09-19	1977-07-05	The Board Of Trustees Of Leland Stanford Junior University	Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en)	1975-11-13	1976-10-05	General Electric Company	Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en)	1976-05-03	1977-07-19	The Massachusetts General Hospital	Composition and method for determining the size and location of myocardial infarcts
US4098876A (en)	1976-10-26	1978-07-04	Corning Glass Works	Reverse sandwich immunoassay
US4331647A (en)	1980-03-03	1982-05-25	Goldenberg Milton David	Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4879219A (en)	1980-09-19	1989-11-07	General Hospital Corporation	Immunoassay utilizing monoclonal high affinity IgM antibodies
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5011771A (en)	1984-04-12	1991-04-30	The General Hospital Corporation	Multiepitopic immunometric assay
US4666828A (en)	1984-08-15	1987-05-19	The General Hospital Corporation	Test for Huntington's disease
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US4801531A (en)	1985-04-17	1989-01-31	Biotechnology Research Partners, Ltd.	Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5272057A (en)	1988-10-14	1993-12-21	Georgetown University	Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en)	1989-08-25	1993-03-09	Genetype Ag	Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
DK0814159T3 (da)	1990-08-29	2005-10-24	Genpharm Int	Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5189178A (en)	1990-11-21	1993-02-23	Galardy Richard E	Matrix metalloprotease inhibitors
US5239078A (en)	1990-11-21	1993-08-24	Glycomed Incorporated	Matrix metalloprotease inhibitors
US5281521A (en)	1992-07-20	1994-01-25	The Trustees Of The University Of Pennsylvania	Modified avidin-biotin technique
US6544761B2 (en) *	1994-12-13	2003-04-08	Human Genome Sciences, Inc.	Human tissue inhibitor of metalloproteinase-4
WO1997000449A1 (en) *	1995-06-14	1997-01-03	Aberdeen University	Prognostic and therapeutic system for cancer
US20020015997A1 (en) *	1997-06-16	2002-02-07	Lafferty William Michael	Capillary array-based sample screening
AU6511199A (en) *	1998-10-08	2000-04-26	Calbiochem Novabiochem Corporation	Diagnostic assay for matrix metalloproteinase 9 and use thereof
WO2002066057A2 (en) *	2001-02-23	2002-08-29	Biophage Inc.	Methods and compositions for preventing and treating neutrophil-mediated diseases
SE0102298D0 (sv)	2001-06-27	2001-06-27	Astrazeneca Ab	Crystal structure of enzyme and uses thereof
WO2003006006A1 (en) *	2001-07-09	2003-01-23	The Regents Of The University Of California	Use of matrix metalloproteinase inhibitors to mitigate nerve damage
US7731648B2 (en) *	2001-07-25	2010-06-08	Aduro Biotech	Magnetic nanoscale particle compositions, and therapeutic methods related thereto
DE60325564D1 (de) *	2002-03-05	2009-02-12	Univ Texas	Biospezifische kontrastmittel
WO2004087042A2 (en) *	2003-04-04	2004-10-14	Yeda Research And Development Co. Ltd.	Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
FI20040572A0 (fi) *	2004-04-23	2004-04-23	Ctt Cancer Targeting Tech Oy	Matriisi-metalloproteinaasin aktiviteetin inhibiittorit
WO2006037513A1 (en) *	2004-10-09	2006-04-13	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with matrix metalloproteinase 9 (mmp9)
KR20100071972A (ko)	2007-08-15	2010-06-29	예다 리서치 앤드 디벨럽먼트 캄파니 리미티드	Ｍｍｐ-9의 조절인자 및 그의 용도

2008
- 2008-08-07 KR KR1020107005028A patent/KR20100071972A/ko not_active Ceased
- 2008-08-07 EP EP12198653.3A patent/EP2581445B1/en not_active Not-in-force
- 2008-08-07 DK DK08789758.3T patent/DK2185175T3/da active
- 2008-08-07 AU AU2008288082A patent/AU2008288082B2/en not_active Ceased
- 2008-08-07 RU RU2010108429/15A patent/RU2474433C2/ru not_active IP Right Cessation
- 2008-08-07 MX MX2010001657A patent/MX2010001657A/es active IP Right Grant
- 2008-08-07 EP EP08789758A patent/EP2185175B1/en not_active Not-in-force
- 2008-08-07 JP JP2010520682A patent/JP2010536744A/ja active Pending
- 2008-08-07 US US12/673,524 patent/US20110052572A1/en not_active Abandoned
- 2008-08-07 CN CN200880112385.3A patent/CN102083455B/zh not_active Expired - Fee Related
- 2008-08-07 BR BRPI0814479A patent/BRPI0814479A2/pt not_active IP Right Cessation
- 2008-08-07 ES ES08789758T patent/ES2406105T3/es active Active
- 2008-08-07 WO PCT/IL2008/001082 patent/WO2009022328A2/en not_active Ceased
- 2008-08-07 CA CA2695969A patent/CA2695969A1/en not_active Abandoned
2012
- 2012-10-09 IL IL222302A patent/IL222302A/en not_active IP Right Cessation
2013
- 2013-06-13 US US13/916,633 patent/US8999332B2/en not_active Expired - Fee Related
2015
- 2015-02-18 US US14/624,597 patent/US20150158953A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2695969A1 (en)	2009-02-19
US20110052572A1 (en)	2011-03-03
ES2406105T3 (es)	2013-06-05
KR20100071972A (ko)	2010-06-29
IL222302A (en)	2016-07-31
US8999332B2 (en)	2015-04-07
AU2008288082A1 (en)	2009-02-19
EP2581445A1 (en)	2013-04-17
MX2010001657A (es)	2010-03-15
CN102083455B (zh)	2015-01-07
EP2185175A2 (en)	2010-05-19
CN102083455A (zh)	2011-06-01
EP2185175B1 (en)	2013-02-13
RU2010108429A (ru)	2011-09-20
EP2185175A4 (en)	2010-08-11
WO2009022328A3 (en)	2010-03-04
WO2009022328A2 (en)	2009-02-19
US20150158953A1 (en)	2015-06-11
JP2010536744A (ja)	2010-12-02
US20130280247A1 (en)	2013-10-24
AU2008288082B2 (en)	2013-01-10
RU2474433C2 (ru)	2013-02-10
EP2581445B1 (en)	2015-04-08
DK2185175T3 (da)	2013-05-13

Publication	Publication Date	Title
BRPI0814479A2 (pt)	2016-07-12	"método para regular uma atividade de metaloproteinase 9 (mm9), método para identificar um agente capaz de regular especificamente a mmp-9, método de tratar a afecção clínica mediada pela mmp-9, molécula capaz de regular especificamente uma atividade da mmp-9, anticorpo humanizado e composição farmacêutica"
BRPI0814957A2 (pt)	2015-02-03	Composto, pró-droga, agente farmacêutico, método para a profilaxia ou tratamento de uma doença, distúrbio ou condição, e, uso do composto.
BRPI0909768A2 (pt)	2015-10-06	composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto
BRPI0905752A2 (pt)	2015-12-01	"muteína de lipocalina da lágrima humana (htlc), molécula de ácido nucléico, célula hospedeira, composição farmacêutica, método para a produção de uma muteína de lipocalina da lágrima humana, método de tratamento de uma doença ou distúrbio e uso de uma mateína de lipocalina da lágrima humana"
BRPI0717219A2 (pt)	2015-05-26	"composição imunogênica, método para tratar ou prevenir doença, e, uso de uma composição imunogênica."
BRPI0815591A2 (pt)	2015-03-03	Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio.
ECSP099833A (es)	2010-01-29	Anticuerpos humanizados contra el globulomero a?(20-42) y sus usos
CY2014042I1 (el)	2015-12-09	Γλυκοπυρανοζυλο-υποκατεστημενα παραγωγα βενζολιου, φαρμακα που περιεχουν τις ενωσεις αυτες, χρηση αυτων και μεθοδος για την παραγωγη τους
BRPI1013763A2 (pt)	2015-08-25	Composto ou sal do mesmo, prodroga, composição farmacêutica, agente diminuidor da proteína de ligação de retinol 4, agente para a profilaxia ou tratamento de diabetes, e, uso de um composto
BRPI0717902A2 (pt)	2013-10-29	"anticorpo monoclonal humano isolado, composição, conjugado anticorpo-molécula parceria, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para prepar um anticorpo anti-cd22, método para inibir o desenvolvimento de uma célula tumoral que expressa cd22 e método para tratar uma doença inflamatória ou autoimuneem um indivíduo"
BRPI0411743A (pt)	2006-08-08	método e composições para tratar doenças relacionadas a amilóides
BRPI0815708A2 (pt)	2014-09-30	Composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição.
BRPI0818244A2 (pt)	2015-06-16	Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BRPI0413977A (pt)	2006-11-07	método para suprimir um distúrbio neovascular, e para tratar um paciente diagnosticado com ou em risco de desenvolver um distúrbio neovascular, composição farmacêutica, e, embalagem farmacêutica
BRPI0915382A2 (pt)	2017-06-27	composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio.
BRPI0819916A2 (pt)	2015-05-19	Proteína de ligação a antígeno, composição farmacêutica, método para tratar um paciente humano afligido com uma doença, anticorpo ou fragmento do mesmo, e, proteína de ligação a antígeno.
BRPI0720169A2 (pt)	2013-12-24	Composto ou um sal do mesmo, prodroga, agente farmacêutico, método para a profilaxia ou tratamento de câncer, e, uso do composto
CL2007003341A1 (es)	2008-04-18	Compuestos derivados de imidazotriazinas; composicion farmaceutica, util para el tratamiento del cancer, arteroesclerosis y enfermedades cardiovasculares entre otras.
BRPI1006215A2 (pt)	2019-09-24	" anticorpos multiespecíficos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, método de tratamento, método de inibição de uma atividade bíologica e uso do anticorpo "
BRPI0906786A2 (pt)	2015-07-14	Composto, processo para a preparação de um composto, uso de um composto, método para o tratamento de uma doença ou condição, composição farmacêutica, processo para a preparação de uma composição farmacêutica, produto, e, kit.
BRPI0811262A2 (pt)	2014-11-04	Composto, composto ou sal do mesmo, composição farmacêutica, modulador de receptor de glicocorticóide, método para prevenção e/ou tratamento de bistúrbios metabólicos, doenças inflamatórias, doenças auto-imunes, doenças alérgicas, doenças do sistema nervoso central, doenças cardiovasculares, doenças relacionadas com homeostase ou glaucoma, e uso de pelo menos um composto ou um sal do mesmo
BR112012003464A2 (pt)	2015-09-08	composto, composição farmacêutica, usos de uma composição farmacêutica e de um composto, e, método para tratar uma doença ou um distúrbio."
BRPI0718586A2 (pt)	2014-03-11	Composto, processo para a sua preparação, composição farmacêutica contendo o mesmo, usos deste e método de tratamento ou prevenção de doenças
BRPI0809680A2 (pt)	2014-10-07	Compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por agonistas de lxr alfa e/ou lxr beta e uso dos compostos.
BR112012003462A2 (pt)	2016-02-23	"composto, composição farmacêutica, e, método para tratar um paciente tendo uma condição mediada pela proteína quinase."

Legal Events

Date	Code	Title	Description
2016-07-19	B15I	Others concerning applications: loss of priority
2016-09-13	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 4A, 5A, 6A, 7A E 8A ANUIDADES.
2017-01-10	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.